phosphorylcholine has been researched along with Epithelial Ovarian Cancer in 4 studies
Phosphorylcholine: Calcium and magnesium salts used therapeutically in hepatobiliary dysfunction.
phosphocholine : The phosphate of choline; and the parent compound of the phosphocholine family.
| Excerpt | Relevance | Reference |
|---|---|---|
| "On the basis of reversal of taxane resistance with AKT inhibition, we initiated a phase I trial of the AKT inhibitor perifosine with docetaxel in taxane and platinum-resistant or refractory epithelial ovarian cancer." | 9.16 | Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer. ( Atkinson, E; Bast, RC; Coleman, RL; Coombes, KR; Dice, K; Dyer, M; Fu, S; Gershenson, DM; Hennessy, BT; Howard, A; Jackson, E; Ju, Z; Kavanagh, JJ; Kundra, V; Kurzrock, R; Levenback, CF; Li, J; Li, Y; Markman, M; Mills, GB; Ng, CS; Sood, AK; Stemke-Hale, K; Wolf, JK, 2012) |
| "On the basis of reversal of taxane resistance with AKT inhibition, we initiated a phase I trial of the AKT inhibitor perifosine with docetaxel in taxane and platinum-resistant or refractory epithelial ovarian cancer." | 5.16 | Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer. ( Atkinson, E; Bast, RC; Coleman, RL; Coombes, KR; Dice, K; Dyer, M; Fu, S; Gershenson, DM; Hennessy, BT; Howard, A; Jackson, E; Ju, Z; Kavanagh, JJ; Kundra, V; Kurzrock, R; Levenback, CF; Li, J; Li, Y; Markman, M; Mills, GB; Ng, CS; Sood, AK; Stemke-Hale, K; Wolf, JK, 2012) |
| "We recently showed that epithelial ovarian cancer (EOC) possesses an altered MRS-choline profile, characterised by increased phosphocholine (PCho) content to which mainly contribute over-expression and activation of choline kinase-alpha (ChoK-alpha)." | 1.40 | Choline kinase-alpha by regulating cell aggressiveness and drug sensitivity is a potential druggable target for ovarian cancer. ( Bagnoli, M; Canevari, S; De Cecco, L; Granata, A; Iorio, E; Mezzanzanica, D; Nicoletti, R; Pisanu, ME; Podo, F; Ricci, A; Tinaglia, V, 2014) |
| "Perifosine-response was associated with the expression (FDR<0." | 1.39 | Perifosine, an AKT inhibitor, modulates ovarian cancer cell line sensitivity to cisplatin-induced growth arrest. ( Abbasi, F; Al Sawah, E; Apte, SM; Bou Zgheib, N; Chen, X; Chon, HS; Judson, PL; Lancaster, JM; Marchion, DC; Ramirez, IJ; Wenham, RM; Xiong, Y, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, Z | 1 |
| Tan, Y | 1 |
| Li, X | 1 |
| Quan, J | 1 |
| Bode, AM | 1 |
| Cao, Y | 1 |
| Luo, X | 1 |
| Al Sawah, E | 1 |
| Chen, X | 1 |
| Marchion, DC | 1 |
| Xiong, Y | 1 |
| Ramirez, IJ | 1 |
| Abbasi, F | 1 |
| Bou Zgheib, N | 1 |
| Chon, HS | 1 |
| Wenham, RM | 1 |
| Apte, SM | 1 |
| Judson, PL | 1 |
| Lancaster, JM | 1 |
| Granata, A | 1 |
| Nicoletti, R | 1 |
| Tinaglia, V | 1 |
| De Cecco, L | 1 |
| Pisanu, ME | 1 |
| Ricci, A | 1 |
| Podo, F | 1 |
| Canevari, S | 1 |
| Iorio, E | 1 |
| Bagnoli, M | 1 |
| Mezzanzanica, D | 1 |
| Fu, S | 1 |
| Hennessy, BT | 1 |
| Ng, CS | 1 |
| Ju, Z | 1 |
| Coombes, KR | 1 |
| Wolf, JK | 1 |
| Sood, AK | 1 |
| Levenback, CF | 1 |
| Coleman, RL | 1 |
| Kavanagh, JJ | 1 |
| Gershenson, DM | 1 |
| Markman, M | 1 |
| Dice, K | 1 |
| Howard, A | 1 |
| Li, J | 1 |
| Li, Y | 1 |
| Stemke-Hale, K | 1 |
| Dyer, M | 1 |
| Atkinson, E | 1 |
| Jackson, E | 1 |
| Kundra, V | 1 |
| Kurzrock, R | 1 |
| Bast, RC | 1 |
| Mills, GB | 1 |
1 trial available for phosphorylcholine and Epithelial Ovarian Cancer
| Article | Year |
|---|---|
Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Disease-Free Su | 2012 |
3 other studies available for phosphorylcholine and Epithelial Ovarian Cancer
| Article | Year |
|---|---|
DHRS2 inhibits cell growth and metastasis in ovarian cancer by downregulation of CHKα to disrupt choline metabolism.
Topics: Carbonyl Reductase (NADPH); Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Proliferation; Cho | 2022 |
Perifosine, an AKT inhibitor, modulates ovarian cancer cell line sensitivity to cisplatin-induced growth arrest.
Topics: Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Survival; Cisplatin; Hu | 2013 |
Choline kinase-alpha by regulating cell aggressiveness and drug sensitivity is a potential druggable target for ovarian cancer.
Topics: Carcinoma, Ovarian Epithelial; Cell Death; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chol | 2014 |